TLDR
- MetaVia soars as vanoglipel shows promise in MASH and metabolic treatment.
- MTVA stock jumps after liver and glucose gains from vanoglipel trial.
- Vanoglipel hits key endpoints in MASH study, boosting MetaVia’s outlook.
- MetaVia reports major liver and metabolic wins in Phase 2a results.
- MTVA spikes as new MASH data supports vanoglipel’s dual-action potential.
MetaVia Inc.(MTVA) surged over 11% as the company unveiled compelling Phase 2a results for vanoglipel in MASH treatment. The stock traded near $0.94, reacting sharply to early gains, before settling at $0.95.
MetaVia Inc., MTVA
MetaVia Inc. now gains strong attention following data that show vanoglipel’s dual mechanism in metabolic and liver pathways.
Vanoglipel Shows Clinically Meaningful Benefits in MASH and Glycemic Control
MetaVia Inc. confirmed that vanoglipel achieved substantial metabolic and hepatic improvements over 16 weeks of treatment. The compound reduced glycated hemoglobin (HbA1c) levels from week four, maintaining consistent reductions through week sixteen. This occurred without weight loss, indicating a direct mechanism of glucose regulation via GPR119 agonism.
The Phase 2a study enrolled 109 participants with metabolic dysfunction-associated steatohepatitis (MASH), assigning them to placebo or three vanoglipel treatment arms. These included two monotherapy doses and a combination with a DPP4 inhibitor to enhance GLP-1 action. MetaVia Inc. stated that the combination extended GLP-1 activity while monotherapy alone yielded robust biochemical improvements.
Vanoglipel monotherapy led to an average HbA1c reduction of –0.54 percentage points by week sixteen. The combination arm further enhanced this with a decrease of –0.66 percentage points. MetaVia Inc. emphasized that even patients without diabetes showed strong glucose control enhancements.
MetaVia Inc. Highlights Liver Function Gains and Anti-Fibrotic Effects
MetaVia Inc. noted a sharp decline in alanine transaminase (ALT) in patients with elevated baseline levels. These reductions were primarily driven by vanoglipel alone, as combination therapy did not show added hepatic benefit. This reinforces the compound’s ability to protect liver function independently.
The treatment reduced liver steatosis based on imaging parameters, including CAP and VCTE. MetaVia Inc. also observed reductions in liver stiffness and improved FAST and NIS-4 non-invasive diagnostic scores. These results support vanoglipel’s potential to treat both liver inflammation and fibrosis.
Vanoglipel decreased markers linked to liver cell death, inflammation, and fibrosis. MetaVia Inc. reported lower levels of CK18F, hs-CRP, and TIMP1, consistent with liver protection. These findings align with earlier biochemical trends seen across treated groups.
Plasma Lipid Profile Shifts Strengthen MetaVia Inc.’s Clinical Outlook
MetaVia Inc. revealed that vanoglipel 100 mg significantly changed lipidomic profiles associated with hepatic damage. The drug lowered harmful glycerolipids and glycerophospholipids linked to liver injury. These improvements may contribute to long-term metabolic stability and hepatic repair.
The compound reduced disease-associated lipid markers such as DG36:4, TG52:4, PE38:4, and PE38:5. MetaVia Inc. confirmed that these reductions occurred consistently across participants receiving higher vanoglipel doses. This adds to the drug’s differentiated mechanism targeting both lipid metabolism and liver health.
Vanoglipel was well tolerated across all study arms, with no discontinuations from adverse effects except in the placebo group. MetaVia Inc. underlined the strong safety profile supporting further development. The company plans to continue advancing vanoglipel in future MASH treatment programs.
MetaVia Inc. now positions vanoglipel as a single-agent or combination option for cardiometabolic and liver conditions. The company presented this new data at The Liver Meeting® 2025 hosted by AASLD in Washington, D.C. With its stock climbing, MetaVia Inc. continues gaining momentum in the clinical-stage biotech space.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
